The mid-stage study tested the oral drug, AKB-6548, against a
placebo for 20 weeks in non-dialysis patients.
Some patients with chronic kidney disease suffer from anemia due to
the body's inability to produce red blood cells in response to lower
oxygen levels caused by the progressive loss of kidney function.
(Reporting by Natalie Grover in Bangalore; Editing by Sriraj
[to top of second column]
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.